Oral and Intravenous Amoxicillin Dosing Recommendations in Neonates: A Pooled Population Pharmacokinetic Study

被引:4
|
作者
Keij, Fleur M. [1 ,2 ,15 ]
Schouwenburg, Stef [3 ,4 ]
Kornelisse, Rene F. [1 ]
Preijers, Tim [3 ,4 ]
Mir, Fatima [5 ]
Degraeuwe, Pieter [6 ]
Stolk, Leo M. [7 ]
van Driel, Arianne [8 ]
Kenter, Sandra [2 ]
van der Sluijs, Jacqueline [9 ]
Heidema, Jojanneke [10 ]
den Butter, Paul C. P. [11 ]
Reiss, Irwin K. M. [1 ]
Allegaert, Karel [3 ,12 ,13 ]
Tramper-Stranders, Gerdien A. [1 ,2 ]
Koch, Birgit C. P. [3 ,4 ]
Flint, Robert B. [1 ,3 ,4 ,14 ]
机构
[1] Erasmus MC, Sophia Childrens Hosp, Dept Paediat, Div Neonatol, Rotterdam, Netherlands
[2] Franciscus Gasthuis & Vlietland, Dept Paediat, Rotterdam, Netherlands
[3] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands
[4] Erasmus MC, Rotterdam Clin Pharmacometr Grp, Rotterdam, Netherlands
[5] Aga Khan Univ, Sect Paediat Infect Dis, Paediat & Child Hlth, Karachi, Pakistan
[6] Maastricht Univ Med Ctr, Dept Paediat, Div Neonatol, Maastricht, Netherlands
[7] Maastricht Univ Med Ctr, Dept Clin Pharm, Maastricht, Netherlands
[8] IJsselland Hosp, Dept Paediat, Capelle aan den IJssel, Netherlands
[9] Maxima Med Ctr, Dept Paediat, Div Neonatol, Veldhoven, Netherlands
[10] St Antonius Hosp, Dept Paediat, Nieuwegein, Netherlands
[11] Ikazia Hosp, Dept Paediat, Rotterdam, Netherlands
[12] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium
[13] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[14] Erasmus MC, Dept Hosp Pharm, Dept Paediat, Div Neonatol, Postal Box 2040, NL-3000 CA Rotterdam, Netherlands
[15] Erasmus MC, Dept Neonatol, Sophia Childrens Hosp, Postal Box 2040, NL-3000 CA Rotterdam, Netherlands
关键词
amoxicillin; absorption; pharmacokinetics; neonates; CLAVULANIC ACID; OPEN-LABEL; INFANTS; ANTIBIOTICS; INFECTION; REGIMENS; PRETERM;
D O I
10.1093/cid/ciad432
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background There is a lack of evidence on oral amoxicillin pharmacokinetics and exposure in neonates with possible serious bacterial infection (pSBI). We aimed to describe amoxicillin disposition following oral and intravenous administration and to provide dosing recommendations for preterm and term neonates treated for pSBI.Methods In this pooled-population pharmacokinetic study, 3 datasets were combined for nonlinear mixed-effects modeling. In order to evaluate amoxicillin exposure following oral and intravenous administration, pharmacokinetic profiles for different dosing regimens were simulated with the developed population pharmacokinetic model. A target of 50% time of the free fraction above the minimal inhibitory concentration (MIC) with an MICECOFF of 8 mg/L (to cover gram-negative bacteria such as Escherichia coli) was used.Results The cohort consisted of 261 (79 oral, 182 intravenous) neonates with a median (range) gestational age of 35.8 weeks (range, 24.9-42.4) and bodyweight of 2.6 kg (range, 0.5-5). A 1-compartment model with first-order absorption best described amoxicillin pharmacokinetics. Clearance (L/h/kg) in neonates born after 30 weeks' gestation increased with increasing postnatal age (PNA day 10, 1.25-fold; PNA day 20, 1.43-fold vs PNA day 3). Oral bioavailability was 87%. We found that a twice-daily regimen of 50 mg/kg/day is superior to a 3- or 4-times daily schedule in the first week of life for both oral and intravenous administration.Conclusions This pooledpopulation pharmacokinetic description of intravenous and oral amoxicillin in neonates provides age-specific dosing recommendations. We conclude that neonates treated with oral amoxicillin in the first weeks of life reach adequate amoxicillin levels following a twice-daily dosing regimen. Oral amoxicillin therapy could therefore be an adequate, cost-effective, and more patient-friendly alternative for neonates worldwide. This pharmacokinetic study shows that the maturing clearance of amoxicillin is impacted by postnatal- and gestational age. A twice-daily regimen of 50 mg/kg/day oral amoxicillin is noninferior to a 3- or 4-times daily regimen and needs adjustment with increasing age.
引用
收藏
页码:1595 / 1603
页数:9
相关论文
共 50 条
  • [21] Population Pharmacokinetic Study of Vancomycin in Preterm Neonates
    Caceres Guido, Paulo
    Travaglianti, Monica
    Castro, Graciela
    Licciardone, Nieves
    Ferreyra, Oscar
    Vietri, Silvia
    Mato, Gabriel
    Niselman, Viviana
    Schaiquevich, Paula
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (01): : 124 - 133
  • [22] Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens
    Abdalla, S.
    Briand, C.
    Oualha, M.
    Bendavid, M.
    Beranger, A.
    Benaboud, S.
    Treluyer, J-M
    Zheng, Y.
    Capito, C.
    Demir, Z.
    Foissac, F.
    Winter, S.
    Gana, I
    Boujaafar, S.
    Bouazza, N.
    Hirt, D.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [23] Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: Dosing recommendations
    Toublanc, Nathalie
    Sargentini-Maier, Maria Laura
    Lacroix, Brigitte
    Jacqmin, Philippe
    Stockis, Armel
    CLINICAL PHARMACOKINETICS, 2008, 47 (05) : 333 - 341
  • [24] Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study
    Wacharachaisurapol, Noppadol
    Sukkummee, Warumphon
    Anunsittichai, Orawan
    Srisan, Panida
    Sangkhamal, Siriporn
    Chantharit, Prawat
    Vandepitte, Warunee Punpanich
    Wattanavijitkul, Thitima
    Puthanakit, Thanyawee
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 109 : 230 - 237
  • [25] A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea
    Rodriguez, GI
    Kuhn, JG
    Weiss, GR
    Hilsenbeck, SG
    Eckardt, JR
    Thurman, A
    Rinaldi, DA
    Hodges, S
    Von Hoff, DD
    Rowinsky, EK
    BLOOD, 1998, 91 (05) : 1533 - 1541
  • [26] PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF ORAL AND INTRAVENOUS PENBUTOLOL
    VEDIN, JA
    WILHELMSSON, C
    MAASS, L
    PETERSON, LE
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 25 (04) : 529 - 534
  • [27] An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study
    Hirt, Deborah
    Van Overmeire, Bart
    Treluyer, Jean-Marc
    Langhendries, Jean-Paul
    Marguglio, Arnaud
    Eisinger, Mark J.
    Schepens, Paul
    Urien, Saik
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 629 - 636
  • [28] Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
    Janssen, Esther J. H.
    Valitalo, Pyry A. J.
    Allegaert, Karel
    de Cock, Roosmarijn F. W.
    Simons, Sinno H. P.
    Sherwin, Catherine M. T.
    Mouton, Johan W.
    van den Anker, Johannes N.
    Knibbe, Catherijne A. J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (02) : 1013 - 1021
  • [29] OPTIMIZING VANCOMYCIN DOSING AND MONITORING IN NEONATES AND INFANTS USING POPULATION PHARMACOKINETIC MODELING.
    Jarugula, P.
    Arikan, A.
    Munoz, F.
    Moffett, B.
    Gobburu, J.
    Ivaturi, V.
    Rios, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S11 - S11
  • [30] OPTIMIZING VANCOMYCIN DOSING AND MONITORING IN NEONATES AND INFANTS USING POPULATION PHARMACOKINETIC MODELING.
    Jarugula, P.
    Arikan, A.
    Munoz, F.
    Moffett, B.
    Gobburu, J.
    Ivaturi, V.
    Rios, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S27 - S27